Madrigal Pharmaceuticals, Inc. MDGL Other Commercial Liabilities
Other Commercial Liabilities at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s other commercial liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s other commercial liabilities?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported other commercial liabilities of $275.76M in Q1 2026.
- How has Madrigal Pharmaceuticals, Inc.'s other commercial liabilities changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s other commercial liabilities increased by 122.1% year-over-year, from $124.17M to $275.76M.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s other commercial liabilities?
- Over 5 years (2020 to 2025), Madrigal Pharmaceuticals, Inc.'s other commercial liabilities has grown at a 41.9% compound annual growth rate (CAGR), from $45.22M to $260.39M.